Skip to main content
SpringerLink
Log in

Hormones sexuelles

  • Chapter
Manifestations dermatologiques des maladies d’organes

  • 711 Accesses

Résumé

Ce chapitre est principalement consacré à la prise en charge diagnostique et thérapeutique des hyperandrogénies. Seront également abordées les manifestations dermatologiques associées à la ménopause, la prise d’œstroprogestatifs ainsi que les affections dermatologiques ayant un lien direct avec les stéroïdes sexuels.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Pelletier G, Ren L. Localization of sex steroid receptors in human skin. Histol Histopathol 2004; 19:629–636.

    PubMed  CAS  Google Scholar 

  2. Kovacs WJ. The androgen receptor. In Androgen excess disorders in women. Azziz R, Nestler JE, Dewailly D, eds, Lippincott-Raven, Philadelphia, 1997, p. 53–61, ch. 6.

    Google Scholar 

  3. Sawaya ME, Shalita AR. Androgen receptor polymorphisms (CAG repeat lengths) in androgenetic alopecia hirsutism and acne. J Cutan Med Surg 1998; 3:9–15.

    PubMed  CAS  Google Scholar 

  4. Calvo RM, Asuncion M, Sancho J et al. The role of the CAG repeat polymorphism in the androgen receptor gene and of skewed X-chromosome inactivation in the pathogenesis of hirsutism. J Clin Endocrinol Metab 2000; 85: 1735–1740.

    Article  PubMed  CAS  Google Scholar 

  5. Mowszowicz I, Melanitou E, Doukani A et al. Androgen binding capacity and 5 alphareductase activity in pubic skin fibroblasts from hirsute patients. J Clin Endocrinol Metab 1983; 56:1209–1213.

    Article  PubMed  CAS  Google Scholar 

  6. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: Implications, etiology, and management. Am J Obstet Gynecol 1981; 140:815–830.

    PubMed  CAS  Google Scholar 

  7. Ayoub N, Rouphael N, Tomb R. [Hirsutism]. Ann Dermatol Venereol 2002; 129:1140–1150.

    PubMed  CAS  Google Scholar 

  8. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21:1440–1447.

    Article  PubMed  CAS  Google Scholar 

  9. Redmond GP. Clinical evaluation of the woman with an androgenic disorder. In Androgenic disorders. Redmond GD, ed, Raven Press, New York, 1995, p. 1–20.

    Google Scholar 

  10. Strickler JH, Garrett AB. Androgen excess and hair loss in women. In Androgen excess disorders in women. Azziz R, Nestler JE, Dewailly D, eds, Lippincott-Raven, Philadelphia, 1997, p. 141–147, ch. 14.

    Google Scholar 

  11. Cavelier-Balloy B, Assouly P. [Role and limitations of skin biopsy in the diagnosis of alopecia]. Ann Dermatol Venereol 2009; 136:182–198.

    Article  PubMed  CAS  Google Scholar 

  12. AFSSAPS Traitement de l’acné par voie générale: argumentaire. Ann Dermatol Venereol 1999; 126:224–231.

    Google Scholar 

  13. Dreno B, Alirezai M, Auffret N et al. Corrélation clinique et psychologique dans l’acné: utilisation des grilles ECLA et CADI. Ann Dermatol Venereol 2007; 134:451–455.

    Article  PubMed  CAS  Google Scholar 

  14. Dreno B, Finlay AY, Nocera T et al. The Cardiff Acne Disability Index: cultural and linguistic validation in French. Dermatology 2004; 208:104–108.

    Article  PubMed  Google Scholar 

  15. Azziz R, Sanchez LA, Knochenhauer ES et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004; 89:453–462.

    Article  PubMed  CAS  Google Scholar 

  16. Cortet-Rudelli C, Desailloud R, Dewailly D. Drug-induced androgen excess. In Androgen excess disorders in women. Azziz R, Nestler JE, Dewailly D, eds, Lippincott-Raven, Philadelphia, 1997, p. 613–621, ch. 59.

    Google Scholar 

  17. Schiebinger RJ, Chrousos GP, Cutler GB Jr et al. The effect of serum prolactin on plasma adrenal androgens and the production and metabolic clearance of dehydroepiandrosterone sulfate in normal and hyperprolactinemic subjects. J Clin Endocrinol Metab 1986; 62:202–209.

    Article  PubMed  CAS  Google Scholar 

  18. Hagag P, Hertzianu I, Ben-Shlomo A et al. Androgen suppression and clinical improvement with dopamine agonists in hyperandrogenic hyperprolactinemic women. J Reprod Med 2001; 46:678–684.

    PubMed  CAS  Google Scholar 

  19. Regnier C, Bennet A, Malet D et al. Intraoperative testosterone assay for virilizing ovarian tumor topographic assessment: report of a Leydig cell tumor of the ovary in a premenopausal women with an adrenal incidentaloma. J Clin Endocrinol Metab 2002; 87:3074–3077.

    Article  PubMed  CAS  Google Scholar 

  20. Pugeat M, Mirakian P, Dutrieux-Berger N, Forest MG, Tourniaire J. Androgen secreting ovarian neoplasms. In Androgen excess disorders in women. Azziz R, Nestler JE, Dewailly D, eds, Lippincott-Raven, Philadelphia, 1997, p. 555–568, ch. 54.

    Google Scholar 

  21. Tita P, Spina A, Briguglia G et al. Clinical features and hormonal characteristics in a case of ovarian arrhenoblastoma. J Endocrinol Invest 1996; 19:484–487.

    PubMed  CAS  Google Scholar 

  22. Derksen J. Androgen secreting adrenal neoplasms. In Androgen excess disorders in women. Azziz R, Nestler JE, Dewailly D, eds, Lippincott-Raven, Philadelphia, 1997, p. 545–553, ch. 53.

    Google Scholar 

  23. Azziz R, Dewailly D Diagnosis, screening and treatment of nonclassic 21-hydroxylase deficiency. In Androgen excess disorders in women. Azziz R, Nestler JE, Dewailly D, eds, Lippincott-Raven, Philadelphia, 1997, p. 181–192, ch. 18.

    Google Scholar 

  24. Degitz K, Placzek M, Arnold B et al. Congenital adrenal hyperplasia and acne in male patients. Br J Dermatol 2003; 148:1263–1266.

    Article  PubMed  CAS  Google Scholar 

  25. White PC, Johrer K, Kofler R. Steroid 11 beta-hydroxylase deficiency. In Androgen excess disorders in women. Azziz R, Nestler JE, Dewailly D, eds, Lippincott-Raven, Philadelphia, 1997, p. 193–200, ch. 19.

    Google Scholar 

  26. Pang S. Inherited 3 beta-hydroxysteroid dehydrogenase deficiency disorder. In Androgen excess disorders in women. Azziz R, Nestler JE, Dewailly D, eds, Lippincott-Raven, Philadelphia, 1997, p. 201–213, ch. 20.

    Google Scholar 

  27. Charmandari E, Kino T, Souvatzoglou E et al. Natural glucocorticoid receptor mutants causing generalized glucocorticoid resistance: molecular genotype, genetic transmission, and clinical phenotype. J Clin Endocrinol Metab 2004; 89:1939–1949.

    Article  PubMed  CAS  Google Scholar 

  28. Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81:19–25.

    Google Scholar 

  29. Ortega-Gonzalez C, Luna S, Hernandez L et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:1360–1365.

    Article  PubMed  CAS  Google Scholar 

  30. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003; 327: 951–953.

    Article  PubMed  CAS  Google Scholar 

  31. Ibanez L, Potau N, Marcos MV, De Zegher F. Adrenal hyperandrogenism in adolescent girls with a history of low birthweight and precocious pubarche. Clin Endocrinol (Oxf) 2000; 53: 523–527.

    Article  CAS  Google Scholar 

  32. Nestler JE, Whitfield JB, Williams TY et al. Genetics of serum dehydroepiandrosterone sulfate and its relationship to insulin in a population-based cohort of twin subjects. J Clin Endocrinol Metab 2002; 87:682–686.

    Article  PubMed  CAS  Google Scholar 

  33. Nagamani M. Polycystic ovarian syndrome variants: hyperthecosis. In Reproductive endocrinology, surgery and technology. Adashi EY, Rock JA, Rosenwaks Z, eds, Lippincott-Raven, Philadelphia, 1996, p. 1257–1269, ch. 63.

    Google Scholar 

  34. Hughesdon PE. Morphology and morphogenesis of the Stein Leventhal ovary and of so-called «hyperthecosis». Obstet Gynecol Surv 1982; 37:59–77.

    Article  PubMed  CAS  Google Scholar 

  35. Azziz R, Carmina E. Idiopathic hirsutism: definition, prevalence and inheritance. In Androgen excess disorders in women. Azziz R, Nestler JE, Dewailly D, eds, Lippincott-Raven, Philadelphia, 1997, p. 529–534, ch. 51.

    Google Scholar 

  36. Futterweit W, Dunaif A, Yeh H, Kingsley P. The prevalence of hyperandrogenism in 109 consecutive females with diffuse alopecia. J Am Acad Dermatol 1988; 5:831–836.

    Article  Google Scholar 

  37. Slayden SM, Moran C, Sams WM Jr et al. Hyperandrogenemia in patients presenting with acne. Fertil Steril 2001; 75:889–892.

    Article  PubMed  CAS  Google Scholar 

  38. Arnaldi G, Angeli A, Atkinson AB et al. Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 2003; 88:5593–5601.

    Article  PubMed  CAS  Google Scholar 

  39. Chanson P, Bertherat J, Beckers A et al. Consensus français sur la prise en charge de l’acromégalie. Ann Endocrinol 2009; 70:92–106.

    Article  CAS  Google Scholar 

  40. Rayfield EJ, Rose LI, Cain JP et al. ACTH-responsive, dexamethasone-suppressible adrenocortical carcinoma. N Engl J Med 1971; 284:591–592.

    Article  PubMed  CAS  Google Scholar 

  41. Kaltsas GA, Isidori AM, Kola BP et al. The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women. J Clin Endocrinol Metab 2003; 88:2634–2643.

    Article  PubMed  CAS  Google Scholar 

  42. Kendall JW, Sloop PR. Dexamethasone-suppressible adrenocortical tumor. N Engl J Med 1968; 279:532–535.

    Article  PubMed  CAS  Google Scholar 

  43. Caron P, Cogne M, Rumeau JL et al. Androgenic granulosa cell tumor of the ovary: in vivo hormonal studies. J Endocrinol Invest 1993; 16: 545–548.

    PubMed  CAS  Google Scholar 

  44. Fiet J, Gueux B, Gourmelen M et al. Comparison of basal and adrenocorticotropinstimulated plasma 21-deoxycortisol and 17-hydroxyprogesterone values as biological markers of late-onset adrenal hyperplasia. J Clin Endocrinol Metab 1988; 66:659–667.

    Article  PubMed  CAS  Google Scholar 

  45. Pang S, Wang M, Jeffries S et al. Normal and elevated 3 alpha androstane diol glucuronide concentrations inwomenwith various causes of hirsutism and its correlation with degree of hirsutism and androgen levels. J Clin Endocrinol Metab 1992; 75:243–248.

    Article  PubMed  CAS  Google Scholar 

  46. Rittmaster RS, Zwicker H, Thompson Konok G, Norman RW. Androstanediol glucuronide production in human liver prostate and skin: evidence for the importance of the liver in 5 alpha reduced androgen metabolism. J Clin Endocrinol Metab 1993; 76:977–982.

    Article  PubMed  CAS  Google Scholar 

  47. Manieri C, Di Bisceglie C, Fornengo R et al. Postmenopausal virilization in a woman with gonadotropin dependent ovarian hyperthecosis. J Endocrinol Invest 1998; 21:128–132.

    PubMed  CAS  Google Scholar 

  48. Deharo C, Berbis P, Privat Y. Complications dermatologiques des contraceptifs oraux. Fertil Contracept Sex 1988; 16:299–304.

    PubMed  CAS  Google Scholar 

  49. McClamrock HD, Adashi EY. Gestational hyperandrogenism. Fertil Steril 1992; 57:257–274.

    PubMed  CAS  Google Scholar 

  50. Morishima A, Grumbach MM, Simpson ER et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995; 80:3689–3698.

    Article  PubMed  CAS  Google Scholar 

  51. Ibanez L, Potau N, Virdis R et al. Postpubertal outcome in girls diagnosed of premature pubarche during childhood: increased frequency of functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1993; 76:1599–1603.

    Article  PubMed  CAS  Google Scholar 

  52. Van Wayjen RG, Van den Ende A. Experience in the long-term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations: efficacy, metabolic and endocrine effects. Exp Clin Endocrinol Diabetes 1995; 103:241–251.

    Article  PubMed  Google Scholar 

  53. Jasonni VM, Bulletti C, Naldi S et al. Treatment of hirsutism by an association of oral cyproterone acetate and transdermal 17-betaestradiol. Fertil Steril 1991; 55:742–745.

    PubMed  CAS  Google Scholar 

  54. Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs 2003; 63:463–492.

    Article  PubMed  CAS  Google Scholar 

  55. Ludicke F, Johanisson E, Helmerhorst FM et al. Effect of a combined oral contraceptive containing 3 mg of drospirenone and 30 μg of ethinyl-estradiol on the human endometrium. Fertil Steril 2001; 76:102–107.

    Article  PubMed  CAS  Google Scholar 

  56. Moghetti P, Tosi F, Tosti A et al. Comparison of spironolactone, flutamide and finasteride efficacy in the treatment of hirsutism: a randomized, double-blind placebo-controlled trial. J Clin Endocrinol Metab 2000; 85:89–94.

    Article  PubMed  CAS  Google Scholar 

  57. Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. Fertil Steril 2003; 79:91–95.

    Article  PubMed  Google Scholar 

  58. Jamin C. L’alopécie androgénogénétique. Ann Dermatol Venereol 2002; 129:801–803.

    PubMed  CAS  Google Scholar 

  59. Vexiau P, Chaspoux C, Boudou P et al. Effects of minoxidil 2% vs cyproterone acetate treatment on female andrognetic alopecia: a controlled 12-month randomized trial. Br J Dermatol 2002; 146:992–999.

    Article  PubMed  CAS  Google Scholar 

  60. Carey AH, Chan KL, Short F et al. Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. Clin Endocrinol (Oxf) 1993; 38:653–658.

    Article  CAS  Google Scholar 

  61. Finasteride Male Pattern Hair Loss Study Group Long-term(5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol 2002; 12:38–49.

    Google Scholar 

  62. Pierard-Franchimont C, Pierard GR. Postmenopausal aging of the sebaceous follicle: a comparison between women receiving hormone replacement therapy or not. Dermatology 2002; 204:17–22

    Article  PubMed  CAS  Google Scholar 

  63. Sator PG, Schmidt JB, Sator MO et al. The influence of hormone replacement therapy on skin ageing: a pilot study. Maturitas 2001; 39: 43–55.

    Article  PubMed  CAS  Google Scholar 

  64. Baulieu EE, Thomas G, Legrain S et al. Dehydroepiandrosterone (DHEA) DHEA sulfate and aging: contribution of the DHEAge study to a sociobiomedical issue. Proc Natl Acad Sci USA 2000; 97:4279–4284.

    Article  PubMed  CAS  Google Scholar 

  65. Fierens H, Delescluse J. Mélasma. In Thérapeutique dermatologique. Dubertret L, Aractingi S, Bachelez H, Bodemer C, Chosidow O, Cribier B, Joly P. Medecine-Sciences Flammarion, Paris, 2001, p. 535–538.

    Google Scholar 

  66. Herzberg AJ, Strohmeyer CR, Cirillo-Hyland VA. Autoimmune progesterone dermatitis. J Am Acad Dermatol 1995; 32:333–338.

    Article  PubMed  CAS  Google Scholar 

  67. Shelley WB, Shelley ED, Talanin NY, Santoso-Pham J. Estrogen dermatitis. J Am Acad Dermatol 1995; 32:25–31.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Antoine Bennet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Delphine Vezzosi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Philippe Caron
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Bennet, A., Vezzosi, D., Caron, P. (2012). Hormones sexuelles. In: Manifestations dermatologiques des maladies d’organes. Springer, Paris. https://doi.org/10.1007/978-2-287-72073-4_2

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-72073-4_2

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-72072-7

  • Online ISBN: 978-2-287-72073-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation